INmune Bio enters $65M ATM equity distribution agreement with A.G.P.

Inmune Bio, Inc.

Up to $65M of common stock may be sold from time to time through A.G.P. as sales agent.
Commission of 3.0% of gross proceeds; Company not obligated to sell any shares.
Shares offered via shelf registration effective Aug 7, 2024, with prospectus supplement dated Dec 19, 2025.
A.G.P. will use commercially reasonable efforts consistent with Nasdaq rules and state/federal law.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Inmune Bio, Inc. entered into Sales Agreement with A.G.P./Alliance Global Partners valued at up to $65,000,000 (effective 2025-12-19).

Action: entry
Agreement: atm program
Counterparty: A.G.P./Alliance Global Partners
Value: up to $65,000,000
Effective: 2025-12-19

Exact text from the filing

On December 19, 2025, INmune Bio Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through A.G.P., up to $65,000,000 of shares of its common stock

View on SEC.gov

Browse all material agreements →

Inmune Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-123880

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.